1290538-90-7

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 542-92-7 cyclopenta-1,3-diene 

Downstream Products

• 1414848-42-2 (1S,4R,5R)-2-[(S)-1-phenylethyl]-4-azido-2-azabicyclo[3.2.1]octane 
• 1394910-43-0 (1S,4R,5R)-2-[(S)-1-phenylethyl]-4-amino-2-azabicyclo[3.2.1]octane 
• 1290085-20-9 (1S,3S,4R)-2-[(S)-1-phenylethyl]-3-(benzylaminomethyl)-2-azabicyclo[2,2,1]heptane 
• 1290085-13-0 (1S,3S,4R)-2-[(S)-1-phenylethyl]-3-(aminomethyl)-2-azabicyclo[2,2,1]heptane 
• 1290085-10-7 (1S,3S,4R)-2-[(S)-1-phenylethyl]-3-(azidomethyl)-2-azabicyclo[2,2,1]heptane 

Relevant academic research and scientific papers

Novel chiral bridged azepanes: Stereoselective ring expansion of 2-azanorbornan-3-yl methanols

The reaction of 2-azanorbornan-3-yl methanols under Mitsunobu or mesylation conditions with various nucleophiles led to a series of chiral-bridged azepanes with configuration at C-4 dependent on the configuration of the starting alcohol. High yielding, st

2-CYANOPYRROLIDINECARBOXAMIDE COMPOUND

A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is =CH2, =CHF or =CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.] having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.